Ninlaro (ixazomib) — Medica

Initial criteria

• age ≥ 18 years
• Ninlaro will be taken in combination with lenalidomide or cyclophosphamide and dexamethasone OR patient has received at least one prior regimen for multiple myeloma OR the medication will be used following hematopoietic stem cell transplantation OR (patient is not a candidate for bortezomib or Kyprolis [carfilzomib] AND patient is not a transplant candidate)

Approval duration

1 year